Compare Biogen Inc (BIIB) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Linde PLC — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Linde PLC trades at $489.5 (market cap $226.12B). The key difference: Linde PLC is far larger — about 7.5× Biogen Inc's market cap, and Linde PLC pays a 1.3% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | LIN | |
|---|---|---|
Market Cap | $30.13B | $226.12B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $546.64 |
52-Week Low | $128.93 | $389.38 |
Enterprise Value | $37.20B | $249.24B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Linde (LIN) trades at $490.53, up 0.11% on the day, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.50 surpassing expectations. Revenue grew to $34.0B in 2025, with a net income margin of 20.43%. Analysts maintain a strong buy consensus with a $553.60 price target, highlighting robust profitability and dividend growth.
Outlook remains positive due to earnings momentum and sustainability leadership, but risks include elevated valuation multiples and rising debt-to-asset ratio. The stock offers steady income with a $1.60 dividend, yet technical weakness near support at $489 warrants caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
